Filing Flows › CervoMed (CRVO) › Q2 2025
CervoMed (CRVO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 8, 2025
CervoMed (CRVO) reported revenue of $1.8M for the second quarter 2025 (Q2 2025), -47% from a year earlier and -8% from the quarter before. Operating margin was -376.4%, net loss $6.3M (356.1% of revenue).
CervoMed, Q2 2025: revenue $1.8M (-47% year over year), operating margin -376.4%, net loss $6.3M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | -8% | -47% |
| Operating profit | −$6.6M | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | −$6.5M | — | — |
What changed
Revenue was $1.8M in Q2 2025, down 47% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $6.6M, an operating margin of -376.4%. Total costs grew 33% against a revenue fall of 47%. The fastest-growing cost line was Research & development (+35%). The quarter ended with a net loss of $6.3M, wider than the previous quarter's $4.9M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $497K of share-based compensation. Working capital and other items used $753K.
Questions
What was CervoMed's revenue in the second quarter 2025?
CervoMed (CRVO) reported revenue of $1.8M for the second quarter 2025 (Q2 2025), -47% from a year earlier and -8% from the quarter before.
Was CervoMed profitable in the second quarter 2025?
Operating loss was $6.6M (-376.4% of revenue) and net loss $6.3M.
Source: CervoMed 10-Q on SEC EDGAR.